



## **Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference**

June 6, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2018-- [Ironwood Pharmaceuticals, Inc.](http://www.ironwoodpharma.com) (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 39<sup>th</sup> Annual Global Healthcare Conference on Wednesday, June 13<sup>th</sup>, 2018 at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at the Terranea Resort in Rancho Palos Verdes, California.

A live webcast of Ironwood's presentation will be accessible through the Investors section of the company's website at [www.ironwoodpharma.com](http://www.ironwoodpharma.com). To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood's website for 14 days following the conference.

### About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI), or as a fixed-dose combination with allopurinol, for the treatment of hyperuricemia associated with gout. We are also advancing a pipeline of innovative product candidates in areas of significant unmet need, including persistent gastroesophageal reflux disease, diabetic nephropathy, heart failure with preserved ejection fraction, achalasia and sickle cell disease. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit [www.ironwoodpharma.com](http://www.ironwoodpharma.com) or [www.twitter.com/ironwoodpharma](https://twitter.com/ironwoodpharma); information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180606006257/en/>

Source: Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.  
Meredith Kaya, 617-374-5082  
Vice President, Investor Relations and Corporate Communications  
[mkaya@ironwoodpharma.com](mailto:mkaya@ironwoodpharma.com)